A Study of RO5045337 in Patients With Solid Tumors
| Status: | Completed |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 8/3/2016 |
| Start Date: | August 2010 |
| End Date: | May 2013 |
An Open-Label, Randomized 3-Way Crossover, Study to Examine the Food-Effect on Pharmacokinetics of the Current Formulation and Relative Bioavailability of Two New Formulations for RO5045337 in Patients With Solid Tumors Including Lymphoma
This open-label, randomized, cross-over study will evaluate the effect of food on the
pharmacokinetics of single oral doses of RO5045337 in patients with solid tumors. The
anticipated time on study treatment is 3 weeks.
pharmacokinetics of single oral doses of RO5045337 in patients with solid tumors. The
anticipated time on study treatment is 3 weeks.
Inclusion Criteria:
- Adult patients, >/=18 years of age
- Histologically confirmed solid tumor
- Life expectancy of >/=12 weeks
- ECOG performance status of 0 or 1
- Adequate bone marrow, renal and hepatic function
Exclusion Criteria:
- Patients receiving any other investigational agent or therapy administered with the
intention to treat their malignancy within 28 days prior to study start
- Patients with pre-existing gastro-intestinal disorder
- Patients with uncontrolled intercurrent illness
We found this trial at
5
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials